Cargando…

(18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study

BACKGROUND: Positron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of (18)F-JK-PSMA-7 PET/CT for local and nodal...

Descripción completa

Detalles Bibliográficos
Autores principales: Vierasu, Irina, Van Simaeys, Gaetan, Trotta, Nicola, Lacroix, Simon, Bormans, Guy, Albisinni, Simone, Quackels, Thierry, Roumeguère, Thierry, Goldman, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868215/
https://www.ncbi.nlm.nih.gov/pubmed/36683076
http://dx.doi.org/10.1186/s41824-022-00161-2
_version_ 1784876483264643072
author Vierasu, Irina
Van Simaeys, Gaetan
Trotta, Nicola
Lacroix, Simon
Bormans, Guy
Albisinni, Simone
Quackels, Thierry
Roumeguère, Thierry
Goldman, Serge
author_facet Vierasu, Irina
Van Simaeys, Gaetan
Trotta, Nicola
Lacroix, Simon
Bormans, Guy
Albisinni, Simone
Quackels, Thierry
Roumeguère, Thierry
Goldman, Serge
author_sort Vierasu, Irina
collection PubMed
description BACKGROUND: Positron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of (18)F-JK-PSMA-7 PET/CT for local and nodal staging in patients with intermediate- and high-risk prostate cancer (PCa) prior to radical prostatectomy, as compared to conventional imaging techniques. METHODS: We enrolled a total of 10 patients with intermediate- and high-risk PCa diagnosed by multiparametric-MRI followed by systematic and targeted biopsies, eligible for radical prostatectomy with extended lymph node dissection. Clinical team was blind to the results of the pre-surgery (18)F-JK-PSMA-7 PET/CT at times of clinical decision and surgery. One month post-surgery, 18F-JK-PSMA-7 PET/CT was repeated and the results of both scans were unblinded. A third (18)F-JK-PSMA-7 PET/CT could be acquired at a later time point depending on PSA progression. RESULTS: All pre-surgery (18)F-JK-PSMA-7 PET/CT was positive in the prostatic region, while MRI was negative in the prostate in one patient. We also detected positive pelvic lymph nodes in two patients (one high-risk, one intermediate-risk PCa) on pre-surgery and post-surgery (18)F-JK-PSMA-7 PET/CT. No positive pelvic lymph nodes were reported on pre-surgical CT and MRI. (18)F-JK-PSMA-7 PET/CT detected bladder involvement in one patient and seminal vesicles involvement in two patients; this malignant extension was undetected by the conventional imaging techniques. SUVmax in prostate lesions had an average value of 11.51 (range 6.90–21.49). SUVmean in prostate lesions had an average value of 7.59 (range 5.26–14.02). CONCLUSION: This pilot study indicates that pre-surgery (18)F-JK-PSMA-7 PET/CT provides valuable information in intermediate- and high-risk PCa, for surgery planning with curative intent.
format Online
Article
Text
id pubmed-9868215
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98682152023-01-24 (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study Vierasu, Irina Van Simaeys, Gaetan Trotta, Nicola Lacroix, Simon Bormans, Guy Albisinni, Simone Quackels, Thierry Roumeguère, Thierry Goldman, Serge Eur J Hybrid Imaging Original Article BACKGROUND: Positron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of (18)F-JK-PSMA-7 PET/CT for local and nodal staging in patients with intermediate- and high-risk prostate cancer (PCa) prior to radical prostatectomy, as compared to conventional imaging techniques. METHODS: We enrolled a total of 10 patients with intermediate- and high-risk PCa diagnosed by multiparametric-MRI followed by systematic and targeted biopsies, eligible for radical prostatectomy with extended lymph node dissection. Clinical team was blind to the results of the pre-surgery (18)F-JK-PSMA-7 PET/CT at times of clinical decision and surgery. One month post-surgery, 18F-JK-PSMA-7 PET/CT was repeated and the results of both scans were unblinded. A third (18)F-JK-PSMA-7 PET/CT could be acquired at a later time point depending on PSA progression. RESULTS: All pre-surgery (18)F-JK-PSMA-7 PET/CT was positive in the prostatic region, while MRI was negative in the prostate in one patient. We also detected positive pelvic lymph nodes in two patients (one high-risk, one intermediate-risk PCa) on pre-surgery and post-surgery (18)F-JK-PSMA-7 PET/CT. No positive pelvic lymph nodes were reported on pre-surgical CT and MRI. (18)F-JK-PSMA-7 PET/CT detected bladder involvement in one patient and seminal vesicles involvement in two patients; this malignant extension was undetected by the conventional imaging techniques. SUVmax in prostate lesions had an average value of 11.51 (range 6.90–21.49). SUVmean in prostate lesions had an average value of 7.59 (range 5.26–14.02). CONCLUSION: This pilot study indicates that pre-surgery (18)F-JK-PSMA-7 PET/CT provides valuable information in intermediate- and high-risk PCa, for surgery planning with curative intent. Springer International Publishing 2023-01-23 /pmc/articles/PMC9868215/ /pubmed/36683076 http://dx.doi.org/10.1186/s41824-022-00161-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Vierasu, Irina
Van Simaeys, Gaetan
Trotta, Nicola
Lacroix, Simon
Bormans, Guy
Albisinni, Simone
Quackels, Thierry
Roumeguère, Thierry
Goldman, Serge
(18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
title (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
title_full (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
title_fullStr (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
title_full_unstemmed (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
title_short (18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
title_sort (18)f-jk-psma-7 pet/ct for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868215/
https://www.ncbi.nlm.nih.gov/pubmed/36683076
http://dx.doi.org/10.1186/s41824-022-00161-2
work_keys_str_mv AT vierasuirina 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy
AT vansimaeysgaetan 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy
AT trottanicola 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy
AT lacroixsimon 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy
AT bormansguy 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy
AT albisinnisimone 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy
AT quackelsthierry 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy
AT roumeguerethierry 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy
AT goldmanserge 18fjkpsma7petctforstagingintermediateorhighriskprostatecancerpatientsbeforeradicalprostatectomyapilotstudy